It's a subdued start to trading with tariff talk dampening US markets. Pharmaceutical and Energy stocks are the unlucky ...

Still in the biotech space, Prescient Therapeutics (ASX:PTX) has secured fast track designation from the US FDA for its oncology therapy PTX100. The company is targeting Cutaneous T Cell Lymphoma ...

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo ... The recombinant human pentraxin-2 (PTX-2) drug is no longer listed in ...

Recently, it received approval from the U.S. Food and Drug Administration (FDA) for its therapy, Bizengri ... into an exclusive agreement granting PTx the rights to commercialize zenocutuzumab ...

In the IVF space, the government has introduced improved funding/access for the hormone therapy Pergoveris ... Immunoncology developer Prescient Therapeutics (ASX:PTX) has opened its first trial site ...

As for PTX, it will support the growth of our projects, the W2 Project which hosts substantial mineralized zones hosting critical metals including Copper, Nickel, Gold and PGEs and our Shining ...

As research continues to shed light on menopause and heart health, it is becoming increasingly clear that hormone therapy used to treat menopausal symptoms in younger, healthy women is not only ...

Cognitive behavioral therapy (CBT) can be an effective part of a management plan for menopause symptoms. It may help relieve symptoms like mood changes, sleep disturbances, and hot flashes.